Tuesday Research Poster Presentations

Poster Display Hours – 8:30 AM - 3:00 PM
Poster Author Discussion Hour – 2:00 PM - 3:00 PM

<table>
<thead>
<tr>
<th>POSTER PRESENTATIONS:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PCN: CANCER</td>
<td>ROWS A-F</td>
</tr>
<tr>
<td>PDB: DIABETES/ENDOCRINE DISORDERS</td>
<td>ROWS G-K</td>
</tr>
<tr>
<td>PIH: INDIVIDUAL'S HEALTH</td>
<td>ROWS K-N</td>
</tr>
<tr>
<td>PIN: INFECTION</td>
<td>ROWS N-R</td>
</tr>
<tr>
<td>PMS: MUSCULAR-SKELETAL DISORDERS</td>
<td>ROWS R-T</td>
</tr>
</tbody>
</table>
## Research Poster Presentations

<table>
<thead>
<tr>
<th>Acceptance Code</th>
<th>PDF Page #</th>
<th>Topic – Subtopic</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCN1-PCN11</td>
<td>194</td>
<td>Cancer - Clinical Outcomes Studies</td>
</tr>
<tr>
<td>PCN12-PCN37</td>
<td>198</td>
<td>Cancer - Cost Studies</td>
</tr>
<tr>
<td>PCN38-PCN47</td>
<td>209</td>
<td>Cancer - Patient-Reported Outcomes &amp; Patient Preference Studies</td>
</tr>
<tr>
<td>PCN48-PCN63</td>
<td>213</td>
<td>Cancer - Health Care Use &amp; Policy Studies</td>
</tr>
<tr>
<td>PDB1-PDB13</td>
<td>220</td>
<td>Diabetes/Endocrine Disorders - Clinical Outcomes Studies</td>
</tr>
<tr>
<td>PDB14-PDB25</td>
<td>225</td>
<td>Diabetes/Endocrine Disorders - Cost Studies</td>
</tr>
<tr>
<td>PDM26-PDB39</td>
<td>230</td>
<td>Diabetes/Endocrine Disorders - Patient-Reported Outcomes &amp; Patient Preference Studies</td>
</tr>
<tr>
<td>PDB40-PDB49</td>
<td>235</td>
<td>Diabetes/Endocrine Disorders - Health Care Use &amp; Policy Studies</td>
</tr>
<tr>
<td>PIH1-PIH4</td>
<td>240</td>
<td>Individual's Health - Clinical Outcomes Studies</td>
</tr>
<tr>
<td>PIH5-PIH9</td>
<td>242</td>
<td>Individual's Health - Cost Studies</td>
</tr>
<tr>
<td>PIH10-PIH15</td>
<td>244</td>
<td>Individual's Health - Patient-Reported Outcomes &amp; Patient Preference Studies</td>
</tr>
<tr>
<td>PIH16-PIH28</td>
<td>246</td>
<td>Individual's Health - Health Care Use &amp; Policy Studies</td>
</tr>
<tr>
<td>PIN1-PIN9</td>
<td>252</td>
<td>Infection - Clinical Outcomes Studies</td>
</tr>
<tr>
<td>PIN10-PIN28</td>
<td>255</td>
<td>Infection - Cost Studies</td>
</tr>
<tr>
<td>PIN29-PIN33</td>
<td>263</td>
<td>Infection - Patient-Reported Outcomes &amp; Patient Preference Studies</td>
</tr>
<tr>
<td>PIN34-PIN41</td>
<td>265</td>
<td>Infection - Health Care Use &amp; Policy Studies</td>
</tr>
<tr>
<td>PMS1-PMS3</td>
<td>269</td>
<td>Muscular-Skeletal Disorders - Clinical Outcomes Studies</td>
</tr>
<tr>
<td>PMS4-PMS12</td>
<td>270</td>
<td>Muscular-Skeletal Disorders - Cost Studies</td>
</tr>
<tr>
<td>PMS13-PMS16</td>
<td>274</td>
<td>Muscular-Skeletal Disorders - Patient-Reported Outcomes &amp; Patient Preference Studies</td>
</tr>
<tr>
<td>PMS17-PMS21</td>
<td>276</td>
<td>Muscular-Skeletal Disorders - Health Care Use &amp; Policy Studies</td>
</tr>
</tbody>
</table>
RESEARCH POSTER PRESENTATIONS - SESSION III

DIABETES - SPECIFIC STUDIES

PCN1 A1 CHEMOTHERAPY, CYTOKINES AND CANCER-RELATED FATIGUE: A SYSTEMATIC REVIEW OF QUANTITATIVE STUDIES IN 1312 PATIENTS
Woldehaimanot TE1, Ng T1, Chan A1, Chan R2, National University of Singapore, Singapore, Singapore, 2Queensland University of Technology, Brisbane, Australia

PCN2 A2 PREVALENCE OF COMORBIDITIES AND HEALTH STATUS AMONG CURRENT CANCER AND CANCER SURVIVORS: AN AUSTRALIAN POPULATION-BASED STUDY
Ng HS1, Roder D, Vitry A, University of South Australia, Adelaide, South Australia, Australia

PCN3 A3 COMPARATIVE EVALUATION OF PRELIMINARY SCREENING METHODS FOR COLORECTAL CANCER IN A MASS SCREENING PROGRAM
Ye D., Chen K, Huang Q, Zhejiang University, Hangzhou, China

PCN4 A4 GEFIGINIB, ERLOTINIB AND CHEMOTHERAPY AS SECOND-LINE TREATMENT FOR PATIENT WITH ADVANCED NON-SMALL LUNG CANCER (NSCLC)
Yang M1, Tan EC1, Chen Y2, National Taiwan University, Taipei, Taiwan, 2Taipei Veterans General Hospital, Taipei, Taiwan

PCN5 A5 A SYSTEMATIC REVIEW OF TYROSINE KINASE INHIBITORS AS FIRST LINE TREATMENT FOR ADVANCED NON SMALL CELL LUNG CANCER
Kamaruzaman HF1, Ku Abd Rahim KN1, Lee SW1, Mohd Darus N1, Sabirin J1, Ministry of Health Malaysia, Federal Territory of Putrajaya, Malaysia

PCN7 A6 THE EFFECTIVENESS ANALYSIS OF SELECTED RADIOSURGERY DEVICES ON TREATMENT OF CANCER TUMORS AND ARTERIOVENOUS MALFORMATIONS: A SYSTEMATIC REVIEW
Davari M1, Afzali M1, Sabbagh-Bani-Azad M1, Sharif Z2, Hadizadeh P3, Mirmoghtadaee P3, Bakrani A2, Hoseini SM4, Kolahdoozan F1, Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), 2Shahid-Beheshti University of Medical Sciences, Tehran, Iran (Islamic Republic of), 3Isfahan University of Medical Science, Isfahan, Iran (Islamic Republic of), 4Medical image & signal processing research center, Isfahan, Iran (Islamic Republic of)

PCN8 A7 PREVALENCE OF SHISHA SMOKING AMONG ADULT MALE CIGARETTE SMOKERS OF MULTAN, PAKISTAN
Aziz MM1, Fang Y1, Ahmed J2, Xi’an Jiaotong University, Xi’an, Shaanxi, P. R. China, Xi’an, China, 2Eli Lilly Pakistan (PVT) LTD, Multan, Pakistan

PCN9 A8 FACTORS INFLUENCING THE PHARMACOKINETICS OF SUNITINIB AND ITS ACTIVE METABOLITE IN MRCC PATIENTS RECEIVING AN ATTENUATED SUNITINIB DOSING REGIMEN
Chae J1, National University of Singapore, Singapore, Singapore

PCN10 A9 REAL WORLD EXPERIENCE OF SUNITINIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA; RESULTS FROM COMPASSIONATE USE PROGRAM IN MALAYSIA
Lee YY1, Lim TO1, Hong LW1, Pfizer Malaysia, Kuala Lumpur, Malaysia, 2StatsConsulting, Petaling Jaya, Malaysia

PCN11 A10 PATIENT CHARACTERISTICS AND CLINICAL OUTCOMES OF PATIENTS WITH LIVER CANCER IN A TERTIARY-CARE HOSPITAL IN MALAYSIA
Shabaruddin FH1, Jamil AA1, Hashim H1, Yunus RM1, Mohamed R1, University of Kuala Lumpur, Kuala Lumpur, Malaysia

CANCER - Cost Studies

PCN12 B1 ECONOMIC EVALUATION OF CANCER MEDICINES USAGE AT UGANDA CANCER INSTITUTE
Mwesige B1, Uganda Cancer Institute, Kampala, Uganda

PCN13 B2 THE EVPI OF TREATMENT STRATEGIES FOR RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
Huang W1, Chen L1, Ting J1, Cao V1, Sung H1, Yokokura M1, Wilson L2, UCSF, San Francisco, CA, USA, 2University of California, San Francisco, San Francisco, CA, USA

PCN14 B3 LITERATURE REVIEW ON HOSPITAL COSTS FOR PATIENTS UNDERGOING GASTRECTOMY
Chen BP1, Cheng H2, Hsiao C3, Ethicon Inc., Somerville, NJ, USA, 2Global Health Economics and Market Access, Ethicon Inc., Cincinnati, OH, USA

PCN15 B4 COST ANALYSIS OF DIFFERENT SEQUENTIAL TREATMENT REGIMENS FOR METASTATIC RENAL CELL CARCINOMA IN CHINA
Wan Y1, Gao C2, Xue M2, Ren H3, Dong P4, Pharmerit International, Bethesda, MD, USA, 2Pharmerit International, Newton, MA, USA, 3Pfizer China, Shanghai, China, 4Pfizer Investment Co., Ltd., Beijing, China

PCN16 B5 BURDEN OF CANCERS ATTRIBUTABLE TO TOBACCO SMOKING IN MEMBER COUNTRIES OF THE ASSOCIATION OF SOUTH EAST ASIAN NATIONS (ASEAN), 2012
Kristina SA1, Endarti D1, Thavorncharoensap M2, 1Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia, 2Mahidol University, Bangkok, Thailand
PCN17 B6  **EFFECTS OF LAPAROSCOPIC SURGERY ON HEALTH OUTCOMES, HEALTH CARE UTILIZATION AND COST IN PATIENTS WITH COLON CANCER: A POPULATION-BASED STUDY USING PROPENSITY SCORE MATCHING**

*Yang M*, Tan EC, Chen C, National Taiwan University, Taipei, Taiwan, 1Sun Yat-Sen Cancer Center, Taipei, Taiwan

PCN19 B7  **ECONOMIC BURDEN OF GEFTINIB VERSUS PEMETREXED FOR INSURED PATIENTS WITH LUNG CANCER IN URBAN XINJIANG PROVINCE, CHINA: A REAL WORLD RESEARCH**

*Mao W*, Chen W, Fudan University, Shanghai, China

PCN20 B8  **PHARMACOECONOMIC EVALUATION OF CANCER TREATMENTS IN INDIA**

*Sundar S*, Rajan S, Nagappa A, Manipal University, Manipal, India, 1SCS College of Pharmacy, Harpanahalli, India

PCN21 B9  **COMPARISON OF COST-EFFECTIVENESS BETWEEN EGFR-TKI THERAPY AND CHEMOTHERAPY FOR ADVANCED NSCLC**

*Zhang T*, Cai S, Wu C, Xu J, Lin T, Jiang J, Jinan University, Guangzhou, China, 2Sun Yat-sen Univerity, Guangzhou, China

PCN22 B10  **CURRENT TRENDS IN METHODS OF PHARMACOECONOMIC STUDIES OF CANCER THERAPIES IN CHINA**

*Ma F*, Cheng X, Aballéa S, Toumi M, 1Creativ-Cellular, Beijing, China, 2Creativ-Cellular, Hong Kong, Hong Kong, 3CREATIV-Ceutical, Paris, France, 4Aix-Marseille University, Marseille, France

PCN23 C1  **IMPLICATIONS OF PRICE EROSION OF DOCETAXEL AFTER LOSS OF EXCLUSIVITY ON COST-EFFECTIVENESS**

*Kim H*, Bae S, Liew D, 1University of Melbourne, Parkville, Australia, 2Ewha Womans University, Seoul, South Korea, 3Monash University, Melbourne, Australia

PCN24 C2  **COST-EFFECTIVENESS OF BRENXTUIMAB VEDOTIN IN RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT IN TAIWAN**

*Zou D*, Kendall R, Lin Q, Huang Y, Tieng J, Sajosi P, 1ICON plc, Vancouver, BC, Canada, 2Kantar Health, Taipei, Taiwan, 3Takeda Pharmaceuticals Taiwan, Taipei, Taiwan, 4Takeda Pharmaceuticals International AG, Zurich, Switzerland

PCN26 C3  **COST-EFFECTIVENESS OF RITUXIMAB IN THE TREATMENT OF DIFFUSE LARGE B-CELL NON-HODGKIN’S LYMPHOMA PATIENTS (DLBCL) IN CHINA**

*Chen W*, Xu C, Fudan University, Shanghai, China, 1Shanghai Roche Pharmaceuticals Ltd., Shanghai, China

PCN27 C4  **DON’T PUT OFF UNTIL TOMORROW WHAT YOU CAN DO TODAY: COST-EFFECTIVENESS OF TRASTUZUMAB PLUS PACLITAXEL COMBINATION THERAPY AND SEQUENTIAL USE OF PACLITAXEL AND TRASTUZUMAB IN THE TREATMENT OF METASTATIC BREAST CANCER IN SINGAPORE**

*Plietscher M*, Carreras M, Wong A, Doshi R, Hoffmann-La Roche Ltd, Basel, Switzerland, 1Roche Singapore Pte Ltd, Singapore, Singapore

PCN28 C5  **THE CLINICAL AND ECONOMIC IMPACT OF SCHOOL-BASED QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE ON FEMALE OR BOTH GENDERS IN SINGAPORE**

*Tay SK*, 1Hsu T, Shcheprov A, Waila A, Kulkarni AS, 1Singapore General Hospital, Singapore, Singapore, 2MSD Pharma (Singapore) Pte Ltd., Singapore, Singapore, 2Merck & Co., Inc., Kenilworth, NJ, USA, 3MSD International GmbH (Singapore Branch), Singapore, Singapore, 4Merck & Co. Inc, Rahway, NJ, USA

PCN29 C6  **OPTIMAL AND ENSURE TRIALS - BASED COMBINED COST-EFFECTIVENESS ANALYSIS OF EROLTINIB VERSUS CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF ASIAN PATIENTS WITH NONSQUAMOUS NON- small-Cell Lung Cancer**

*Wen P*, Zheng H, Zhang P, Hutton DW, Li Q, 1West China Hospital, Sichuan University, Chengdu, China, 2University of Michigan, Michigan, MI, USA

PCN30 C7  **COST-EFFECTIVENESS OF SURGICAL EXCISION VS MOHS MICROGRAPHIC SURGERY FOR NON-MELANOMA SKIN CANCER**

*Maracy MR*, Nasiripour L, Amirsadri MR, Tabatabaeian M, Isfahan University of Medical Sciences, Isfahan, Iran (Islamic Republic of)

PCN31 C8  **ECONOMIC EVALUATION OF CERVICAL CANCER SCREENING STRATEGIES IN CHINA**

*Lu X*, Chen W, Chen W, Lang J, 1Roche Diagnostics Limited, Shanghai, China, 2Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China, 3Fudan University, Shanghai, China, 4Peking Union Medical College Hospital, Beijing, China

PCN32 C9  **COST-EFFECTIVENESS ANALYSIS OF OXALIPLATIN PLUS FLUOROURACIL/LEUCOVORIN (FOLFOX4) COMPARED TO SORAFENIB FOR TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA PATIENTS IN CHINA**

*Qin SK*, Kruger E, Tan SC, Cheng SQ, Yao XX, Liang J, 1Department of medical oncology, People’s Liberation Army Cancer Center, Eight One Hospital, Nanjing, China, 2Economics and Outcomes, Real World Evidence, IMS Health, Singapore, 3Department of hepatic surgery, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China, 4Health economic and outcome research, Sanofi, Shanghai, China, 5Department of medical oncology, Peking University tumor hospital, Peking University international hospital, Beijing, China

PCN33 C10  **COST EFFECTIVENESS OF BRCA MUTATION TESTING FOR EARLY-STAGE BREAST CANCER PATIENTS WITH FAMILY HISTORY IN MALAYSIA**
PCN34 D1 TAMOXIFEN FOR THE PRIMARY PREVENTION OF BREAST CANCER: NEW LIFE FOR AN OLD DRUG
Alexander PR, Optum, Lillyfield, Australia

PCN35 D2 ECONOMIC EVALUATION OF FIRST LINE TREATMENT FOR ADVANCED NON SMALL CELL LUNG CANCER USING TYROSINE KINASE INHIBITORS IN MALAYSIA
Ku Abd Rahim KN1, Kamaruzaman HF1, Shafie AA2, Hussain S3, Sabirin J1, 1Ministry of Health Malaysia, Federal Territory of Putrajaya, Malaysia, 2Univ Sains Malaysia, Penang, Malaysia, 3University of Malaya, Kuala Lumpur, Malaysia

PCN36 D3 A COST-UTILITY ANALYSIS OF THE RISK-GUIDED ANTIEMETIC PROPHYLAXIS VERSUS PHYSICIAN'S CHOICE IN PATIENTS RECEIVING CHEMOTHERAPY FOR EARLY-STAGE BREAST CANCER: A NET-BENEFIT REGRESSION APPROACH
Thavorn K1, Vandermeer L1, Mazzarello S2, Wang Z2, Clemons M1, The Ottawa Hospital, Ottawa, ON, Canada, 1University of Ottawa, Ottawa, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada

PCN37 D4 A TIME AND MOTION COST ANALYSIS OF ORAL VINORELBINE VERSUS IV CHEMOTHERAPIES FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AND METASTATIC BREAST CANCER (MBC) FROM CHINESE SOCIETAL PERSPECTIVE
Zhang L1, Crowell V1, Ai X2, Berdeaux G3, Zheng H4, Xuan J5, Shanghai Centennial Scientific, Shanghai, China, 2Shanghai Chest Hospital, Shanghai, China, 3Pierre Fabre Medicament, Boulogne-Billancourt, France, 4Shanghai Market Access Medicament Technology Developing Co., Ltd, Shanghai, China, 5Sun Yat-Sen University, Guangzhou, China

CANCER - Patient-Reported Outcomes & Patient Preference Studies

PCN38 D5 A COMPARISON OF HEALTH STATE UTILITIES AMONG BREAST CANCER PATIENTS IN MAINLAND CHINA
Li S1, Wang M2, Xu X1, Chen G3, 1Shandong University, Jinan, China, 2Qingdao Municipal Hospital, Qingdao, China, 3Flinders University, Adelaide, Australia

PCN39 D6 IMPACT OF PATIENTS COUNSELLING ON MINDFUL ATTENTION AWARENESS AND STRESS IN CANCER PATIENTS
Yiragamreddy SR1, P.T.priyanka P, Yiragamreddy Pr, Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, India

PCN40 D7 BREAST CANCER IN JAPAN: ROOM FOR IMPROVED SCREENING
Vietri J1, Stankus AP2, Fukuda T3, 1Kantar Health, Horsham, PA, USA, 2National Institute of Public Health, Wako, Japan

PCN41 D8 PATIENT PREFERENCES VERSUS PHYSICIAN PERCEPTIONS OF TREATMENT DECISIONS IN ADVANCE STAGE PROSTATE CANCER
Yoshizawa K1, Mahlich J2, Nakayama M1, Kobayashi H1, Takahashi Y2, Saito K3, Tsubota A1, Uemura H3, Masayuki T1, Janssen KK, Tokyo, Japan, 1ANTERIO Inc., Tokyo, Japan, 2Yokohama City University Medical Center, Yokohama-city, Japan, 3Kitasato Hospital, Hokiaido, Japan

PCN42 D9 PREFERENCE FOR CERVICAL CANCER SCREENING IN RURAL CHINA: A DISCRETE CHOICE EXPERIMENT
Li S1, Ratcliffe J1, Chen G2, Shandong University, Jinan, China, 1Flinders University, Adelaide, Australia

PCN43 D10 DESIGNING A DISCRETE CHOICE EXPERIMENT TO MEASURE PATIENT PREFERENCES AND WILLINGNESS-TO-PAY FOR TARGETED THERAPIES FOR COLORECTAL CANCER IN SINGAPORE
Wong XY1, Chia JW2, Chew MH3, Tan WS1, Wee HL1, 1National University of Singapore, Singapore, Singapore, Singapore, 2National Cancer Centre Singapore, Singapore, Singapore, 3Singapore General Hospital, Singapore, Singapore

PCN44 E1 THE RELATIONSHIP BETWEEN REGRET IN PATIENT DECISION-MAKING DURING THE CLINICAL PROCESS AND PATIENT FACTORS—TESTS BASED ON THE JAPANESE VERSION OF THE DECISION REGRET SCALE(DRS)—
Tanno K1, Bito S2, Rikkyo University, Tokyo, Japan, 1National Hospital Organization Tokyo Medical Center, Tokyo, Japan

PCN45 E2 PATIENT-REPORTED OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE OVERALL AND JAPANESE POPULATIONS FROM ELOquent-2
McKendrick J1, Zyczynski T2, Kudlac A1, Davis C2, Cella D3, 1PRMA Consulting Ltd, Fleet, UK, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3Northwestern University, Chicago, IL, USA

PCN46 E3 PATIENT REPORTED OUTCOMES IN JAPANESE ONCOLOGY PRODUCTS - REVIEW OF THE PMDA LABELS
Crawford B1, Kim HR2, 1IMS Japan K.K., Minato-ku, Tokyo, Japan, 2IMS Japan KK, Minato-ku, Tokyo, Japan

PCN47 E4 USING GEOGRAPHICAL INFORMATION SYSTEMS TO DESCRIBE QUALITY OF LIFE AS A FUNCTION OF DISTANCE IN CANCER PATIENTS
Hayran KM, Erman M, Kilickap S, Dizdar Ö, Yuce D, Huseyin B, Celik I, Hacettepe University Cancer Institute, Ankara, Turkey

CANCER - Health Care Use & Policy Studies

PCN48 E5 THE IMPACT OF CANCER PREVENTION AND TREATMENT POLICY ON INCREASING INCIDENCE OF EARLY-STAGE CANCER IN TAIWAN
Hsieh W, Kuo C, Lin Y, Chen C, Chang C, Tang C, Taipei Medical University, Taipei, Taiwan
PDB3  G3  INDIRECT COMPARISON OF TRIAMCINOLONE ACETONIDE WITH RANIBIZUMAB AND AFLIBERCEPT FOR THE TREATMENT OF DIABETIC MACULAR EDEMA
Park S, Choi YR, Jeung S, Choi I, Suh D, Chung-Ang University, Seoul, South Korea

PDB4  G4  LIPID LEVELS AND GLYCAEMIC CONTROL IN MALAYSIAN DIABETES PATIENTS
Abdat A1, Azmi S1, Feisul Mi2, Goh A1, Abdul Aziz SH1, Azmi Burhani Consulting, Petaling Jaya, Malaysia, 2Ministry of Health, Malaysia, Putrajaya, Malaysia

PDB5  G5  DO MORE MEN OR WOMEN WITH T2DM ACHIEVE THEIR GLYCAEMIC TARGETS? AN EXPLORATORY MALAYSIAN STUDY
Azmi S1, Feisul Mi2, Abdat A1, Goh A1, Abdul Aziz SH1, Azmi Burhani Consulting, Petaling Jaya, Malaysia, 2Ministry of Health, Malaysia, Putrajaya, Malaysia

PDB6  G6  HEPARIN AND RELATED SUBSTANCES FOR TREATING DIABETIC FOOT ULCERS
Su N, Xu T, West China Hospital of Sichuan University, Chengdu, China

PDB7  G7  EVALUATION OF GLYCEMIC CONTROL WITH THE COMBINATION OF BIPHASIC INSULIN AND METFORMIN THERAPY IN TYPE 2 DIABETES MELLITUS PATIENTS
Sirajudeen SA, King Khalid University, Abha, Saudi Arabia

PDB8  G8  IATROGENIC HYPOGLYCAEMIA IN THE ELDERLY: AN ANALYSIS OF DIABETIC MEDICATION USAGE PATTERNS ACCORDING TO AGE
Goh A1, Azmi S1, Feisul Mi2, Abdat A1, Abdul Aziz SH1, Azmi Burhani Consulting, Petaling Jaya, Malaysia, 2Ministry of Health, Malaysia, Putrajaya, Malaysia

PDB9  G9  NEED FOR ENHANCED GLUCOSE SCREENING IN PREGNANT WOMEN IN INDONESIA
Fitria N, van Asselt A, Postma MJ, University of Groningen, Groningen, The Netherlands

PDB10 G10  PRESENCE OF LIPOHYPERTROPHY AND ITS RELATION TO INSULIN INJECTION PRACTICES IN PATIENTS WITH TYPE 1 DIABETES MELLITUS
Barola A1, Tiwari P1, Bhansali A2, Grover S2, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), Punjab, India, 2Post Graduate Institute of Medical Education & Research, Chandigarh, India

PDB11 H1  RISK FACTORS OF CARDIOVASCULAR DISEASE IN MALAYSIAN DIABETES PATIENTS
Azmi S1, Feisul Mi2, Abdat A1, Goh A1, Abdul Aziz SH1, Azmi Burhani Consulting, Petaling Jaya, Malaysia, 2Ministry of Health, Malaysia, Putrajaya, Malaysia

PDB12 H2  METFORMIN TREATMENT AND HOMOCYSTEINE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Li S, Zhang Q, Li L, Li Q, Ren K, Yu C, Kwong J, Sun X, Li J, West China Hospital of Sichuan University, Chengdu, China

PDB13 H3  TIME TO DIABETES RELATED COMPLICATIONS FOR NEWLY DIAGNOSED DIABETES PATIENTS IN SINGAPORE
Saxena N, Kannapiran P, Ang YQ, National Healthcare Group, Singapore, Singapore, Singapore

DIABETES/ENDOCRINE DISORDERS - Cost Studies

PDB14 H4  GESTATIONAL DIABETES SCREENING FOR CHINESE WOMEN: A COST-EFFECTIVENESS ANALYSIS
Ming WK, SUN YAT-SEN UNIVERSITY, Guangzhou, China

PDB15 H5  ESTIMATION OF NATIONAL ECONOMIC BURDEN OF HYPOGLYCAEMIA AMONG TYPE 2 DIABETES MELLITUS PATIENTS IN MALAYSIA
Alijunid SM1, Nur A2, Ismail A2, Aung YN3, 1Kuwait University, Kuwait City, Kuwait, 2Universiti Kebangsaan Malaysia, Cheras, Malaysia, 3UCSI University, Cheras, Malaysia

PDB16 H6  FACTORS ASSOCIATED WITH GLYCEMIC CONTROL AND DIABETES-RELATED COSTS IN PATIENTS WITH DIABETES IN THE UNITED ARAB EMIRATES: RESULTS FROM A RETROSPECTIVE LARGE CLAIMS DATA ANALYSIS
CHOI YC, Lee YJ, Lee SH, Chang C, Song I, Suh D, Chung-Ang University, Seoul, South Korea

PDB17 H7  COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 50 VERSUS BIPHASIC HUMAN INSULIN 50 IN PEOPLE WITH TYPE 2 DIABETES MELLITUS IN CHINA
Wang H1, Liu X2, Wan L1, Sun Y3, Chen K4, Zhang Y5, Yancheng Tinghu People's Hospital, Yancheng, China, 2Dongtai Peoples’ Hospital, Yancheng, China, 3Jiangsu Funing People's Hospital, Yancheng, China, 4Novo Nordisk(China) Pharmaceuticals Co., Ltd, Beijing, China

PDB18 H8  COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS ACARBOSE AS A MONOTHERAPY IN TYPE 2 DIABETES IN CHINA
Gu S1, Dong H2, Zhejiang University, Hangzhou, China, 2Zhejiang University, Hangzhou, China

PDB19 H9  THE COST-EFFECTIVENESS OF DULAGLITIDE VERSUS LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TAIWAN
Lin H1, Babineaux S2, Lew T1, Lowin J3, Lovato E3, Strizek AA4, Rajan N5, 1Eli Lilly and Company (Taiwan), Inc, Taipei, Taiwan, 2Eli Lilly and Company, Indianapolis, IN, USA, 3IMS Health, London, UK, 4Lilly Australia, sydney, Australia, 5Eli Lilly
PDB20  H10  COST-EFFECTIVENESS OF INSULIN DEGLUDEC TREATMENT IN PATIENTS WITH TYPE1 AND TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW
Yue X1, Guan HJ2, Wu J3, Bai X4, University of Cincinnati, Cincinnati, OH, USA, 2Peking University China Center for Health Economic Research, Beijing, China, 3The 306th Hospital of PLA, Beijing, China

PDB21  I1  COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN VERSUS GLIMEPIRIDE AS MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CHINA
Shao H, Shi L, Tulane University, New Orleans, LA, USA

PDB22  I2  COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS ACARBOSE AS SECOND-LINE THERAPY IN TYPE 2 DIABETES IN CHINA
Gu S1, Shao H2, Zeng Y3, Shi L4, Dong H5, Zhejiang University, Hangzhou, China, 3Tulane University, New Orleans, LA, USA

PDB24  I3  REVIEW OF ECONOMIC EVALUATION OF SAXAGLITPIN IN TYPE2 DIABETES IN CHINA
Zhang C1, HU C1, Xu L2, AstraZeneca(China), Beijing, China, 2AstraZeneca (China), Beijing, China

PDB25  I4  THE LONGTERM EFFECTIVENESS OF THE “COACHING PATIENTS ON ACHIEVING CARDIOVASCULAR HEALTH” (COACH) PROGRAM IN TYPE 2 DIABETES IN TASMANIA
Palmer AJ1, Vale MJ1, Wells CL2, Ski C3, Thompson DR4, Si L5, 1Menzies Institute for Medical Research, Hobart, Australia, 2Australian Catholic University, Melbourne, Australia, 3Diabetes Tasmania, Hobart, Australia, 4University of Tasmania, Hobart, Australia

DIABETES/ENDOCRINE DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

PDB26  I5  SELF-CARE BEHAVIOR AND MEDICATION USE OF BUDDHIST MONKS WITH DIABETES MELLITUS IN PHASE CHAROEN, BANGKOK
Yensabai J1, Torthear P2, Neamsripetch V1, Karndee A1, Pongmesa T1, Luckanajantachote P2, 1Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand, 2Department of Pharmacy, Samut Sakhon Hospital, Samut Sakhon, Thailand

PDB27  I6  ADHERENCE OF PATIENTS WITH TYPE 2 DIABETES TO MEDICATIONS – THE ROLE OF RISK PREFERENCES
Simon-Tuval T1, Shmueli A2, Harman-Boehm I3, Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2The Hebrew University of Jerusalem, Jerusalem, Israel, 3Ben-Gurion University of the Negev; Soroka University Medical Center, Beer-Sheva, Israel

PDB28  I7  DISEASE RELATED KNOWLEDGE, MEDICATION ADHERENCE AND GLYCAEMIC CONTROL AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS IN PAKISTAN
Nazir SU1, Hassail MA2, 1School of Pharmaceutical Sciences, Penang, Malaysia, 2Universiti Sains Malaysia, Penang, Malaysia

PDB29  I8  STUDY ON MEDICATION ADHERENCE BEHAVIOR AND QUALITY OF LIFE IN ELDERLY DIABETIC, HYPERTENSION PATIENTS IN A TERTIARY CARE HOSPITAL: A PROSPECTIVE STUDY
katta Venkatesh R1, M.M.Prabhu M1, K.S.R. Pai KK2, Krishnad K3, Krishnakumar KK4, 1MCOPS, Manipal University, Manipal & BG Nagar, India, 2KMCH, Manipal university, Manipal, India, 3MCOPS, Manipal University, Manipal, India

PDB30  I9  EFFECT OF A PAY-FOR-PERFORMANCE PROGRAM FOR DIABETES ON HEALTH STATUS (EQ-5D) IN TAIWAN
Chen T1, Lang HC2, Fu Jen Catholic University, NewTaipei, Taiwan, 2National Yang-Ming University, Taipei, Taiwan

PDB31  I10 HIGHER WEIGHT, HIGHER BURDEN: OUTCOMES OF ADULTS IN JAPAN WITH TYPE 2 DIABETES
Vietri J1, Fukuda T2, Stankus AP3, 1Kantar Health, Horsham, PA, USA, 2National Institute of Public Health, Wako, Japan, 3University of Balochistan, Quetta, Pakistan

PDB32  J1  PREFERENCES FOR TREATMENT ATTRIBUTES OF DULAGLUTIDE AND LIRAGLUTIDE AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS AND THEIR WILLINGNESS TO SELF-INJECT DIABETES MEDICATION: A COMPARISON BETWEEN JAPAN AND THE UNITED KINGDOM
Gelhorn HL1, Bacci ED2, Poon JL3, Boye KS4, Suzuki SJ5, Babineaux S6, 1Evidera, Bethesda, MD, USA, 2Evidera, Seattle, WA, USA, 3Eli Lilly and Company, Indianapolis, IN, USA, 4Eli Lilly Japan KK, Tokyo, Japan

PDB33  J2  ASSESSMENT OF KNOWLEDGE AND PRACTICE REGARDING FOOT CARE OF DIABETES MELLITUS PATIENT IN TERTIARY CARE HOSPITALS, QUETTA, PAKISTAN
ul Haq N, Durran P, Nasim A, Razaque G, Ahmed N, Muhammad S, Raiz S, University of Balochistan, Quetta, Pakistan

PDB35  J3  EFFECTIVENESS OF SELF-MONITORING OF BLOOD GLUCOSE (SMBG) IN REDUCING HBA1C OF DIABETES MELLITUS TYPE-2 PATIENTS IN JAKARTA, INDONESIA: PRELIMINARY FINDINGS
Istanti ND1, University of Indonesia, Indonesia, 2Nerd Medis, Jakarta, Indonesia

PDB36  J4  TRANSLATION, ADAPTATION AND VALIDATION OF THE DIABETES DISTRESS SCALE FOR INDONESIAN DIABETIC OUTPATIENTS WITH VARIOUS TYPES OF COMPLICATIONS
Arifin B1, Perwitasari D2, Atthobari J2, Cao Q3, Krabbe PF4, 1University of Groningen the Netherlands, Groningen, The Netherlands, 2University of Ahmad Dahlan Yogyakarta, Yogyakarta, Indonesia, 3Medical Faculty, Universitas Gadjah Mada, Yogyakarta, Indonesia, 4University of Groningen, Groningen, The Netherlands

PDB37  J5  AN OBSERVATIONAL STUDY ON HELATH RELATED QUALITY OF LIFE IN DIABETES MELLITUS PATIENTS
Thunla P., Gundepogu UJ, Thumma P, Baira R, St. Peter's Institute of Pharmaceuticals, Hanamkonda, India, St. Peter's Institute of pharmaceutical sciences, hanamkonda, India

PDB38 J6 PSYCHOMETRIC PROPERTIES OF THE CHINESE VERSION OF PROBLEM AREAS IN DIABETES SCALE (SG-PAID-C) AMONG HIGH-RISK POLYPHARMACY PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES IN SINGAPORE
Siaw M1, Tai B2, Lee J1, National University of Singapore, Singapore, Singapore, 2Caritas Institute of Higher Education and Caritas Bianchi College of Careers, Hong Kong, Hong Kong

PDB39 J7 INCREASING TREND OF HEALTH RELATED QUALITY OF LIFE AWARENESS FOR DIABETIC CARE AMONG INDIAN SCIENTISTS
Chawla R1, Katiyar P1, Hughes R2, Purohit D1, AccuScript Consultancy, Ludhiana, India, 2AccuScript Consultancy, Reading, UK

DIABETES/ENDOCRINE DISORDERS - Health Care Use & Policy Studies

PDB40 J8 MARKETING SITUATION AND MEDICAL REFORM POLICY ANALYSIS OF ORAL HYPOGLYCEMIC DRUGS IN CHINA
Long E1, Zhou N2, Yang N2, Hu M2, Zhou L2, 1Sichuan Provincial People’s Hospital, Chengdu, China, 2Sichuan University, Chengdu, China

PDB41 J9 STUDY OF PRESCRIBING PATTERN OF ANTI-DIABETIC DRUGS IN NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS
Merry R1, Vijayanarayana K1, Ginish T1, Nair S1, Karthik Rao N2, 1Dept. of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka State., India, 2Dept. of Medicine, Kasturba Medical College, Manipal University, Manipal, India

PDB42 J10 HEALTH CARE DIRECT COST BURDEN OF DIABETES IN MEDICARE BENEFICIARIES WITH OBESITY
Jaiswal R1 University of the Sciences, Philadelphia, Philadelphia, PA, USA

PDB43 K1 ADMINISTRATIVE CLAIMS ANALYSIS OF ALL-CAUSE HEALTHCARE RESOURCE UTILIZATION FOR T2DM WITH CHRONIC COMORBIDITIES PATIENTS IN CHINA
Liu Q1, Chen L2, Kong L1, Hsiao C3, Yue N3, 1Beijing Brainpower Pharma Consulting Co., Ltd., Beijing, China, 2CHIRA, Beijing, China, 3London School of Economics and Political Science, London, UK, 4Global Health Economics and Market Access, Ethicon Inc., Cincinnati, OH, USA, 5Johnson & Johnson Medical Device, Beijing, China

PDB44 K2 PRESCRIPTION DATA IN AUSTRALIA: HOW USEFUL IS THIS ‘BIG’ DATA?
Kim H1, Calcino L2, Calcino G2, 1Bristol-Myers Squibb Australia, Mulgrave, Australia, 2HI Connections, Fisher, Australia

PDB45 K3 INFO-DIABETIC APPROACH FROM CELLULAR PHONE TEXT MASSAGING CAN MINIMIZE THE COMPLEXITIES IN DIABETIC PATIENT CARE
Kumar N, Gupta BK, Shri Ramswaroop Memorial University, Barabanki, India

PDB46 K4 DEVELOPMENT AND EVALUATION OF PATIENT INFORMATION LEAFLETS FOR DIABETIC FOOT ULCER PATIENTS
MK U1, Miraj SS1, Rodrigues GS2, 1Manipal College of Pharmaceutical Sciences, Manipal, India, 2Kasturba Medical College, Manipal, India

PDB47 K5 TREND IN HBA1C LEVELS AMONG PRIMARY CARE DIABETES PATIENTS ADMITTED TO A TERTIARY HOSPITAL IN SINGAPORE IN 2013
Ang YG, Teow KL, National Healthcare Group, Singapore, Singapore, Singapore

PDB48 K6 COMPARISONS OF TREATMENT PATTERNS FOR TYPE 2 DIABETES MELLITUS (T2DM) IN JAPAN AND IN THE UNITED STATES
Anabuki K1, Irwin DE2, Winer I3, lizuka R1, Nishikino R1, Palmer LA4, 1Japan Medical Data Center Co., Ltd., Tokyo, Japan, 2Truven Health Analytics, Chapel Hill, NC, USA, 3Truven Health Analytics, Ann Arbor, MI, USA, 4Truven Health Analytics, Bethesda, MD, USA

PDB49 K7 DEVELOPMENT OF ANTIBIOTIC FOR MANAGEMENT OF AEROBIC BACTERIAL INFECTION IN DIABETIC FOOT ULCER
Miraj SS1, MK U1, Rodrigues GS2, 1Manipal College of Pharmaceutical Sciences, Manipal, India, 2Kasturba Medical College, Manipal, India

INDIVIDUAL’S HEALTH - Clinical Outcomes Studies

PIH1 K8 A COMPARISON OF LONG-TERM ANTICHOLINERGIC BURDEN DERIVED FROM DIFFERENT RISK SCALES WITH ADVERSE CLINICAL OUTCOMES IN THE ELDERLY
Hsu W1, Lin C1, Wen Y1, Chen L1, Hsiao F1, 1National Taiwan University, Taipei, Taiwan, 2Chang Gung University, Taoyuan, Taiwan, 3Taipei Veterans General Hospital, Taipei, Taiwan

PIH2 K9 EFFECT OF VIRUS HEPATITIS DURING PREGNANCY ON MATERNAL AND PERINATAL ADVERSE OUTCOMES: A SYSTEMATIC REVIEW BASED ON OBSERVATIONAL STUDIES
Tan J1, Sun X2, 1School of West China Public Health, Sichuan University, Chengdu, China, 2West China Hospital of Sichuan University, Chengdu, China

PIH3 K10 PREVALENCE, PHARMACEUTICAL EXPENDITURES AND PATIENT’S FACTORS OF HIGH-RISK MEDICATION USED AMONG ELDERLY INPATIENTS AT A DISTRICT HOSPITAL IN THE SOUTH OF THAILAND
Jantakanangkoon C, Ninlamote W, Pannoi T, Walailak University, Nakhon-Sri Thammarat, Thailand
<table>
<thead>
<tr>
<th>ID</th>
<th>Type</th>
<th>Title</th>
<th>Authors, Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIH4</td>
<td>L1</td>
<td>PREVALENCE OF LOW BIRTHWEIGHT AND ITS CORRELATES FROM 2008 TO 2014 IN XINDU COUNTY OF CHENGDU, CHINA</td>
<td>Zhu P, Pan X, Wang Y, Li C, Chen J,Sichuan University, Chengdu, China</td>
</tr>
<tr>
<td>PIH5</td>
<td>L2</td>
<td>ECONOMIC ASSESSMENT OF DYdroGestosterone COMPARED WITH PROGESTERONE FOR THE TREATMENT OF THREATENED ANDHABITUAL MISCARRIAGE IN CHINA</td>
<td>Connolly M, Tian Q, Sierra M, Zhang L, Vaskantrias V, University of Groningen, Groningen, The Netherlands, Peking Union Medical College Hospital, Beijing, China, Global Market Access Solutions, St-Prex, Switzerland, Abbott China, Shanghai, China, Abbott Products Operations AG, Basel, Switzerland</td>
</tr>
<tr>
<td>PIH6</td>
<td>L3</td>
<td>SUPPLEMENTING THE RIGHT WAY: EFFECTIVE COST MANAGEMENT OF MULTIVITAMIN SYRUPS IN A PAEDIATRIC HOSPITAL</td>
<td>Lim KS, Caleb JS,KK Women's and Children's Hospital, Singapore, Singapore</td>
</tr>
<tr>
<td>PIH7</td>
<td>L4</td>
<td>REAL-WORLD EVIDENCE IN THE CONTEXT OF HTA: ON THE EXAMPLE OF UTERINE FIBROIDS TREATMENT IN UKRAINE</td>
<td>Piniazhko O, Zalisak O,Danylo Halytsky Lviv National Medical University, Lviv, Ukraine</td>
</tr>
<tr>
<td>PIH8</td>
<td>L5</td>
<td>DRUG UTILIZATION AND PHARMACOECONOMIC ANALYSIS OF GERIATRIC PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL</td>
<td>Mohamed Saleem TS, Gopinath C, Mahesh K, Sharmila Bhanu T, Annamacharya College of Pharmacy, YSR Kadapa, India</td>
</tr>
<tr>
<td>PIH9</td>
<td>L6</td>
<td>COST-MINIMIZATION ANALYSIS OF BAOFUKANG VERSUS LANGYI IN THE TREATMENT OF VVC</td>
<td>SUN L, Duan X, LU Y, Chen Y, Shenyang Pharmaceutical University, shenyang, China</td>
</tr>
<tr>
<td>PIH10</td>
<td>L7</td>
<td>MEASURING THE INFLUENCE OF PATIENT COUNSELING AT TERTIARY CARE HOSPITAL IN ANTENATAL CARE, SOUTH KARNATAKA, INDIA</td>
<td>Udupa N, Manipal University, Manipal, India</td>
</tr>
<tr>
<td>PIH12</td>
<td>L9</td>
<td>SELF-REPORTED SLEEP QUALITY, DURATION AND HEALTH-RELATED QUALITY OF LIFE IN OLDER CHINESE</td>
<td>Wang P, National University of Singapore, Singapore, Singapore</td>
</tr>
<tr>
<td>PIH13</td>
<td>L10</td>
<td>THE GUARDIANS’ CHOICES AND PREFERENCES FOR IMPORTED SURROGATE VACCINES IN CHINA: BASED ON A SURVEY IN SHENYANG, LIAONING PROVINCE</td>
<td>Hao Y, Sun L, Jia Y, Li R, Hua S, Duan X, Li Y, Shang Y, Tang M, Shenyang Pharmaceutical University, Shenyang, China</td>
</tr>
<tr>
<td>PIH14</td>
<td>M1</td>
<td>ASSESSMENT OF VARIOUS FACTORS INFLUENCING LIFE IN PCOS PATIENTS OF NORTHERN TELANGANA REGION OF INDIA</td>
<td>Talla V, Jupally yR, Subudhi S, Hunsur Nagendra V, Velupula S, Thatikonda K, Talla Padmavathi College of Pharmacy, Warangal, India, Talla Padmavathi College of Pharmacy, Warangal, INDIA, WARANGAL, India, Talla Padmavathi Pharmacy College, Warangal, WARANGAL, India</td>
</tr>
<tr>
<td>PIH15</td>
<td>M2</td>
<td>USING A DISCRETE CHOICE EXPERIMENT TO VALUE INFORMAL CARE PROVIDED TO CHILDREN WITH INTELLECTUAL DISABILITIES</td>
<td>Arora S, Goodall S, Viney R, Einfeld S, University of Technology Sydney, Sydney, Australia, University of Sydney, Sydney, Australia</td>
</tr>
<tr>
<td>PIH16</td>
<td>M3</td>
<td>ANALYSIS OF PATIENTS’ SATISFACTION ON THE IMPLEMENTATION OF ESSENTIAL DRUG SYSTEM IN CHINA</td>
<td>Ren J, Hangzhou Normal University, HANGZHOU, China</td>
</tr>
<tr>
<td>PIH17</td>
<td>M4</td>
<td>CHANGING PATTERNS OF MEDICATION USE AT THE END OF LIFE IN THE ELDERLY</td>
<td>Chuang H, Hsiao F, National Taiwan University, Taipei, Taiwan, Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan</td>
</tr>
<tr>
<td>PIH18</td>
<td>M5</td>
<td>IMPACT OF POVERTY ON HEALTH CARE UTILIZATION IN THE ELDERLY</td>
<td>Lin C, Hsiao F, National Taiwan University, Taipei, Taiwan</td>
</tr>
<tr>
<td>PIH19</td>
<td>M6</td>
<td>THE EFFECT OF REDUCING COST-SHARING FOR CHILDREN ON UTILIZATION OF INPATIENT SERVICES: EVIDENCE FROM JAPAN</td>
<td>Kato H, Goto R, Kyoto University, Kyoto, Japan, Keio University, Yokohama, Japan</td>
</tr>
<tr>
<td>PIH20</td>
<td>M7</td>
<td>The association between loneliness and healthcare utilization among older adults in Singapore</td>
<td></td>
</tr>
</tbody>
</table>
**PIH21 M8**

THE ADOPTION TRENDS OF ROBOTIC-ASSISTED BENIGN HYSTERECTOMY IN UNITED STATES FROM 2008 TO 2014

Moawad G1, Song C2, Levin J3, Tackett S4, Liu E5, George Washington University, Washington, DC, DC, USA, 4Intuitive Surgical, Sunnyvale, CA, USA, 3Intuitive Surgical, Inc., Sunnyvale, CA, USA

**PIH23 M9**

HOUSEHOLD COST OF INJURIES IN CHILDREN UNDER FIVE YEARS IN THE EJISU-JUABENG MUNICIPALITY OF THE ASHANTI REGION, GHANA: A CROSS SECTIONAL STUDY

Amisah J, Kwame Nkrumah University of Science and Technology, KUMASI, Ghana

**PIH24 M10**

TRADITIONAL AND COMPLEMENTARY MEDICINE USE AMONG WOMEN TO CONCEIVE AND DURING PREGNANCY: A LITERATURE REVIEW

Shaukat Ali R1, Farooqui M1, Gnanasan S1, Universiti Teknologi MARA (Bertam campus), Penang, Malaysia, 2Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam, Malaysia

**PIH25 N1**

CLINICAL AND ECONOMIC OUTCOMES OF PHARMACIST-PROVIDED HOME-BASED MEDICATION REVIEW IN THE ELDERLY: A SYSTEMATIC REVIEW AND META-ANALYSIS

Tan SY1, Cheen HH2, Wee HL1, National University of Singapore, Singapore, Singapore, 2Singapore General Hospital, Singapore, Singapore

**PIH26 N2**

ASSOCIATION BETWEEN SUBJECTIVE WELL-BEING AND HEALTH STATUS AMONG THE ELDERLY IN CHINA: THE INFLUENCES OF SOCIAL SUPPORT AND SOCIAL ADJUSTMENT

Bao C1, Chen Kc, Zhejiang University, Hangzhou, Zhejiang, China, 2Zhejiang University, Hangzhou, China

**PIH27 N3**

RELATIONSHIP BETWEEN PERCEPTION OF SEX HORMONES IMBALANCE, DEPRESSION AND COGNITIVE FUNCTION AMONG FEMALE STUDENTS IN INTERNATIONAL MEDICAL UNIVERSITY: A CROSS-SECTIONAL STUDY

Tumkur A, Venkataraman R, Mittal P, Koay LS, Chow SY, International Medical University, Kuala Lumpur, Malaysia

**PIH28 N4**

IMPACT OF SAFETY-RELATED REGULATION ON USE OF CODEINE IN TAIWANESE CHILDREN

Lin C1, Wang C1, Huang W1, Ke W1, Chao P1, Chen W1, Hsiao F2, Taiwan Drug Relief Foundation, Taipei, Taiwan, 2National Taiwan University, Taipei, Taiwan

---

**INFECTION - Clinical Outcomes Studies**

**PIN2 N6**

REVIEWING THE ECONOMIC IMPACT OF EXTENDING THE NATIONAL IMMUNIZATION PROGRAM IN EGYPT

Atef M, Khataby N, Ministry of Health, Cairo, Egypt

**PIN3 N7**

EFFECT OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, ANGIOTENSIN II RECEPTOR BLOCKERS, AND STATINS ON SEPSIS-RELATED OUTCOMES

Lee S1, National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, 2Seoul National University Hospital, Seoul, South Korea

**PIN4 N8**

AUSTRALIAN INFLUENZA NATIONAL SURVEILLANCE DATA (2009 TO 2014) – VARIATIONS BY SEX, AGE GROUP, AND INFLUENZA TYPE

Luscombe G2, 1Western Sydney University, Bathurst, NSW, Australia, 2University of Sydney, Orange, NSW, Australia

**PIN5 N9**

DISEASE BURDEN OF HERPES ZOSTER AND DENGUE PATIENTS ATTENDING TERTIARY CARE HOSPITAL IN MALAYSIA: A FIVE-YEAR POPULATION-BASED STUDY

Cheng W1, Chang H1, Chen L2, Hsiao F1, National Taiwan University Hospital, Taipei, Taiwan, 2National Taiwan University, Taipei, Taiwan

**PIN6 N10**

LONGITUDINAL TREND OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVALENCE RATES IN THE UNITED STATES

Song X1, Truven Health Analytics, Shrewsbury, MA, USA

**PIN7 O1**

A RETROSPECTIVE OBSERVATIONAL COHORT STUDY TO INVESTIGATE TREATMENT OUTCOME OF MRSA PATIENTS ADMINISTERED WITH ANTI-MRSA DRUGS USING LARGE INSURANCE CLAIMS DATA IN JAPAN

Yuasa A1, Murata T2, Kitazaki S3, Li Y1, Yamamoto Y2, Fujimoto Y1, Pfizer Japan Inc, Tokyo, Japan, 2CRECON Medical Assessment Inc., Tokyo, Japan, 3MinaCare co.ltd, Tokyo, Japan

**PIN8 O2**

DETERMINATION OF PREDICTORS OF PROLONGED HOSPITALIZATION AMONG DENGUE PATIENTS ATTENDING TERTIARY CARE HOSPITAL IN MALAYSIA

Malhi TH1, Khan AH2, Sarriff A2, Adnan AS1, Khan YH1, University Sains Malaysia, Pulau Penang, Malaysia, 2University Sains Malaysia, Kuala Lumpur, Malaysia, 3University Sains Malaysia, Kota Bharu, Malaysia

**PIN9 O3**

A STUDY ON EVALUATION OF EFFECTS OF ANTITUBERCULAR DRUGS ON HEPATOMATOLOGICAL AND HEPATO-RENAL FUNCTIONS IN TUBERCULOSIS PATIENTS

Sagar SV, Bodasu M, Pasunoori R, Adepu S, Vurumadla S, St. Peter's Institute of Pharmaceutical Sciences, Hanamkonda, India

---

**INFECTION - Cost Studies**

**PIN10 O4**

ASSESSING THE BROADER ECONOMIC CONSEQUENCES OF HPV PREVENTION IN INDONESIA USING A GOVERNMENT PERSPECTIVE FISCAL ANALYTIC METHOD

Setiawan D1, Kotsopoulos N2, Postma M1, Connolly M1, University of Groningen, Groningen, The Netherlands, 2Health Policy

---
Institute, Athens, Greece, 2Global Market Access Solutions, Switzerland and US, Groningen, The Netherlands

**PIN11 O5** ROLE OF TIERED PRICING POLICY IN IMPROVING ACCESS TO MEDICINES IN INDIA

Soni P1, Gupta SK2, Delhi Institute of Pharmaceutical Sciences & Research, Delhi, India, 2Delhi Institute of Pharmaceutical Sciences and Research, University of Delhi, India., Delhi, India

**PIN13 O6** Cost analysis of levofloxacin 750mg during 5 days vs levofloxacin 500mg during 10 days for the treatment of community-acquired pneumonia under the brazilian public hospital perspective

Tolentino AC1, Seabra E2, Tanaka E3, Hospital Universitario Pedro Ernesto - UERJ/HUPE, Rio de Janeiro, Brazil, 2Hospital universitario Pedro Ernesto, Rio de Janeiro, Brazil, 3CURITIBA’S HEALTH INSTITUTE, CURITIBA , PARANÁ, Brazil

**PIN14 O7** DIRECT MEDICAL COSTS OF HCV PATIENTS USING NATIONAL HEALTH INSURANCE CLAIMS DATA IN SOUTH KOREA

Kang D1, Lim J1, Shin G1, Bae E1, Choi S1, Korea University, Sejong city, South Korea

**PIN15 O8** ECONOMIC BURDEN OF ANTIBIOTIC-RESISTANT NOOSCOMIAL GRAM-NEGATIVE INFECTIONS IN SINGAPORE HOSPITALS

Chen G1, Lim S1, Ma Q1, Ghosh W2, Costello Medical Singapore Pte Ltd, Singapore, Singapore, 2Costello Medical Consulting Ltd, Cambridge, UK

**PIN16 O9** ECONOMIC EVALUATION OF DENQUE VACCINATION IN BANGKOK METROPOLITAN ADMINISTRATION

Liuak W1, Chuenkitmongkol S2, Thongsri W1, Beucher S3, Baurin N4, Thisyakorn U5, 1Health Department, Bangkok Metropolitan Administration, Bangkok, Thailand, 2Sanofi Pasteur, Bangkok, Thailand, 3Sanofi Pasteur, Singapore, Singapore, 4Sanofi Pasteur, Lyon, France, 5Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

**PIN17 O10** TREATMENT PATTERN OF ANTIBIOTICS AND COST ANALYSIS IN SEPSIS PATIENTS: A CROSS SECTIONAL RETROSPECTIVE & PROSPECTIVE STUDY

Erraboina M1, Gopagoni K1, Manthen A2, Bandari S2, Vurumadia S2, 1St.Peter’s Institute of Pharmaceutical Sciences, Hanamkonda, India, 2St Peter’s Institute of Pharmaceutical sciences, Hanamkonda, India

**PIN18 P1** ECONOMIC BURDEN OF COMMUNITY-ACQUIRED PNEUMONIA AMONG ELDERLY

Konomura K1, Nagai H2, Akazawa M3, 1Meiji Pharmaceutical University, Tokyo, Japan, 2National Hospital Organization Tokyo National Hospital, Tokyo, Japan

**PIN19 P2** CRITICAL ISSUES INFLUENCING COST-EFFECTIVENESS ANALYSES OF PNEUMOCOCCAL VACCINE STRATEGY FOR ELDERLY IN JAPAN

Takumoto Y1, Akazawa M1, Igarashi A2, 1Meiji Pharmaceutical University, Tokyo, Japan, 2University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan

**PIN20 P3** COST-EFFECTIVENESS ANALYSIS OF CASPOFUNGIN VERSUS VORICONAZOLE IN THE EMPIRICAL ANTIMICROBIAL THERAPY OF FEBRILE NEUTROPENIA IN CHINA

Wei Y1, Chen Y1, Guo Z1,Fudan University, Shanghai, China

**PIN21 P4** A PARALLEL OBSERVATIONAL AND PROSPECTIVE STUDY ON PHARMACOECONOMIC ANALYSIS AND PRESCRIBING PATTERN OF ANTIBIOTICS IN INFECTIOUS DISEASES

Chenna C1, Bandari S2, Pal M3, Gaddam D4, 1St peter’s Institute of Pharmaceutical sciences, Warangal, India, 2St. Peter’s Institute of Pharmaceutical Sciences, Warangal, India, 3St.Peter’s Institute of Pharmaceutical Sciences, Warangal, Telangana, India, 4St Peter’s Institute of Pharmaceutical science, Warangal, India

**PIN22 P5** ECONOMIC EVALUATIONS OF HAEMOPHILUS INFLUENZAE TYPE B VACCINE: A SYSTEMATIC REVIEW

Chongmelxame B1, Hammanee M2, Phoaphirak W2, Kotirim S2, Chaityakunapruk N1, Naresuan University, Phitsanulok, Thailand, 1Monash University Malaysia, Selangor, Malaysia

**PIN23 P6** ECONOMIC EVALUATION OF PROTEASE INHIBITORS FOR THE TREATMENT OF PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C IN KAZAKHSTAN

Almadiyeva A1, Ibrayev S2, Turgambayeva A3, Nurgozhin T4, Astana Medical University, Astana, Kazakhstan, 2Nazarbayev University, National Laboratory Astana, Astana, Kazakhstan

**PIN24 P7** COST-EFFECTIVENESS OF ROTAVIRUS VACCINATION IN HANGZHOU, CHINA: A COMPARISON BETWEEN TWO VACCINES

Suvantika AA1, Postma MJ2, 1Universitas Padjadjaran, Sumedang, Indonesia, 2University of Groningen, Groningen, The Netherlands

**PIN25 P8** COST-EFFECTIVENESS OF GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) AS ADJUNCTIVE THERAPY IN CANCER PATIENTS WITH ESTABLISHED FEBRILE NEUTROPENIA

Tong WX, Wang XJ, Chan A, National University of Singapore, Singapore, Singapore

**PIN26 P9** COST-EFFECTIVENESS ANALYSIS OF IMPROVED INFLUENZA VACCINATION COVERAGE IN ADULTS AGED 60 YEARS AND OLDER IN BEIJING, CHINA

Cheng X1, Aballea S2, Dorey J3, Zhou J4, Jia Y5, Toumi M6, 1Creativ- Ceutical, Hong Kong, Hong Kong, 2Creativ- Ceutical, Paris, France, 3Creativ-Ceutical, Beijing, China, 4Shenyang Pharmaceutical University, Shenyang, China, 5Aix-Marseille University, Marseille, France

**PIN27 P10** COST-UTILITY ANALYSIS OF ATAZANAVIR/ RITONAVIR 200/100 MG VERSUS ATAZANAVIR/ RITONAVIR 300/100 MG IN...
THAI ADULTS WITH VIROLOGIC SUPPRESSION
Taychakhoonavudh S1, Maneesawangwong N1, Bunupuradah T2, Kiertiburanakul S3, Worrathammasorn T4, Hadnoornun P5, Avihingsanon A6, Chetchotisakd P7, Emery S8, Ruxunratham K, on behalf of the LASA Study Group.1, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand, 2HIV-NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand, 3Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 4HIV-NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand, 5Khon Kaen University, Khon Kaen, Thailand, 6Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia, 7HIV-NAT, the Thai Red Cross AIDS Research Centre and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

PIN28 Q1 CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH HOSPITAL-ACQUIRED PNEUMONIA (HAP)
Han S1, Xie J2, Song H1, Zhang C1, Wu EQ3, Analysis Group, Inc., Beijing, China, 2Analysis Group, Inc., New York, NY, 3Analysis Group, Inc., Boston, MA, USA

INFECTION - Patient-Reported Outcomes & Patient Preference Studies
PIN29 Q2 MEDICATION ADHERENCE AND RISK FACTORS FOR NONADHERENCE AMONG HIV POSITIVE PREGNANT WOMEN TAKING TENEOFIVIR BASED FIXED DOSE COMBINATION REGIMEN IN NIGERIA
Omonaiye O1, AGU KA, WEST AFRICAN POST GRADUATE COLLEGE OF PHARMACISTS, LAGOS, Nigeria

PIN30 Q3 ROLE OF TUBERCULOSIS HOME OBSERVER IN IMPROVING CLINICAL OUTCOME OF PATIENT IN YEMEN
Jaber AA, Universiti Sains Malaysia, Penang, Malaysia

PIN31 Q4 ANTIMICROBIAL AGENTS DISPENSING IN UPPER RESPIRATORY TRACT, GASTROINTESTINAL TRACT INFECTIONS AND INFECTED WOUND IN THAI DRUG STORES IN 2015
Hemrachatanant P1, Kajiptornwadee T1, Korntanasin T1, Auamnyo T2, Pongpech P1, Chulalongkorn University, Bangkok, Thailand, 2Burapha University, Chonburi, Thailand

PIN32 Q5 EVALUATION OF UTILITY INDEX QUALITY OF LIFE IN HEPATITIS PATIENTS IN JAPAN
Yoda T1, Igarashi A2, Sugimori H3, Sato T4, Hirao T2, Kagawa University, Faculty of Medicine, Kagawa, Japan, 2University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan, 3Daito Bunka University, Tokyo, Japan, 4Aoyama Gakuin University, Tokyo, Japan

PIN33 Q6 THE PUBLIC ACCEPTANCE AND WILLINGNESS-TO-PAY (WTP) OF DENGUE VACCINE IN PENANG, MALAYSIA: ASSESSMENT WITH A CONTINGENT VALUATION STUDY
Yeo HY, Shafie AA, Universiti Sains Malaysia, Penang, Malaysia

INFECTION - Health Care Use & Policy Studies
PIN34 Q7 KNOWLEDGE AND PERCEPTION OF MEDICINE, DENTISTRY AND PHARMACY STUDENTS OF MALAYSIAN UNIVERSITY REGARDING EBOLA VIRUS DISEASE (EVD)
Iqbal MZ1, Iqbal MS2, Deneshwary B2, Rahul RR1, Muhammad Tahir M1, Yeoh CC2, Aziz S3, Mohiuddin SG3, 1AIMST University, Bedong, Kedah Darul Aman, Malaysia, 2Mahidol University, Bangkok, Thailand, 3Mahidol University, Bangkok, Thailand, 4AIMST University, Sungai Petani, Malaysia, 5University of Veterinary and Animal Sciences, Lahore, Pakistan, 6University of Veterinary and Animal Sciences, Lahore, Pakistan

PIN35 Q8 PREDICTORS OF RESPONSE TO INTERFERONE/ RIBAVARIN COMBINATION THERAPY IN CHRONIC HEPATITIS C VIRUS INFECTION AT UPPER EGYPT
Kassem AM, Sohag Faculty of Medicine, Sohag, Egypt

PIN36 Q9 EVALUATION OF ANTIMICROBIAL STEWARDSHIP PROGRAMS IN HAINAN, CHINA
Zhou H, Hainan Medical University, Haikou, China

PIN37 Q10 COMMUNITY RESIDENTS’ KNOWLEDGE AND PERCEPTIONS OF ANTIBiotic RESISTANCE IN PENANG, MALAYSIA: FINDINGS AND IMPLICATIONS
Irawati L1, Hassali MA1, Saleem F1, Arashseedy AA2, 1Universiti Sains Malaysia, Penang, Malaysia, 2Qassim University, Qassim, Saudi Arabia

PIN38 R1 COST OF OUTREACH-PROGRAMME TOWARDS SEX WORKERS IN THE NGO AND PRIMARY HEALTH CENTER IN INDONESIA
Sucahya PK1, Nadjib M2, Oktarina R3, 1Center for Health Research Universitas Indonesia, Depok, Indonesia, 2Universitas Indonesia, Depok, Indonesia

PIN39 R2 DEVELOPING A GEOSPATIAL WEB AND MOBILE APPLICATION TO IMPROVE EXPANDED PROGRAM ON IMMUNIZATION IN GHANA: A MHEALTH TECHNOLOGY NOVELTY, 2015
Antoh E1, Davies-Teye B2, Vanotoo L3, Geografiax Solutions and USAID GHANA/RING, Accra, Ghana, 2Drifney Consult Ltd and Ghana Health Service, Accra, Ghana, 3Ghana Health Services and Promise Ghana, Accra, Ghana

PIN40 R3 INTEGRATION OF HIV AIDS PROGRAM INTERVENTION INTO UNIVERSAL HEALTH COVERAGE (UHC) : LESSON LEARNED FROM INDONESIA
Nadjib M1, Sucahya P2, Korib M3, Harimurti P4, Pujiyanto P5, Oktarina R6, Meqraini A1, 1Universitas Indonesia, Depok, Indonesia, 2World Bank, Jakarta, Indonesia

PIN41 R4 APPROACH TO IMPLEMENTATION OF A FEASIBLE ANTIBIOTIC STEWARDSHIP PROGRAM AT A TERTIARY UNIVERSITY PUBLIC HOSPITAL
Berba RP, University of the Philippines-Philippine General Hospital, Manila, Philippines

**MUSCULAR-SKELETAL DISORDERS - Clinical Outcomes Studies**

**PMS1 R5** ACUTE CARDIOVASCULAR ADVERSE REACTION OF COX-2 INHIBITORS AMONG OSTEOARTHRITIS PATIENTS IN TAIWAN
Chang C⁴, Wang Y⁴, Huang Y⁴, Fann CS⁴, Chang CJ¹, Chang Gung University, Tao-Yun, Taiwan, ²Kantar Health, Taipei, Taiwan, ³Academia Sinica, Taipei, Taiwan

**PMS2 R6** CLINICAL EVALUATION OF AMRITHA GUGGULU IN THE MANAGEMENT OF GOUT
Kuvettu H¹, Acharya S², Nagappa AN³, Muniyal Institute Of Ayurveda Medical Sciences, Manipal., Mangalore, India, ²PG Dept. of Kayachikitsa, Muniyal Institute of Ayurveda Medical Sciences, Manipal, India, ³Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India

**PMS3 R7** THE EFFECTIVENESS OF LEAN BODY MASS ANALYSIS USING DUAL ENERGY X-RAY ABSORPTIOMETRY (DEXA) FOR DIAGNOSIS OF SARCOPENIA
Kim SY, National Evidence-based Collaborating Agency, Seoul, South Korea

**MUSCULAR-SKELETAL DISORDERS - Cost Studies**

**PMS4 R8** THE COMPARISONS OF BIOLOGICS WITH METHOTREXATE FOR TREATING RHEUMATOID ARTHRITIS PATIENTS IN TAIWAN: THE USE OF COST-UTILITY ANALYSIS AND BUDGET IMPACT ANALYSIS
Li C¹, Chou P⁵, Chang C⁴, Fann CS², Chang Gung University, Taichung, Taiwan, ²IMS Health Taiwan, Taipei City, Taiwan, ³Chang Gung University, Taoyuan, Taiwan, ⁴Academia Sinica, Taipei, Taiwan

**PMS5 R9** RISK AND BURDEN OF SUBSEQUENT FRACTURES AFTER FIRST OSTEOPOROSIS-RELATED FRACTURE AMONG OSTEOPOROSIS PATIENTS IN TIANJIN, CHINA
Liu X¹, Wang K¹, Chen Y¹, Wu J¹, Tianjin University, Tianjin, China, ²Lilly Suzhou Pharmaceutical Company, Ltd., Shanghai, China

**PMS6 R10** BURDEN OF OSTEOPEOROSIS-RELATED HIP FRACTURE IN ASIA. A REVIEW OF HEALTH CARE COSTS AND RESOURCE UTILIZATION
Mohd Tahir NA¹, Thomas P², Li SC¹, ¹University of Newcastle, Callaghan, NSW, Australia, ²Taylor's University, Selangor, Malaysia

**PMS7 S1** EVALUATION OF HEALTH CARE COSTS AND UTILIZATION PATTERNS FOR PATIENTS WITH GOUT IN TAIWAN
Lee Y¹, Ko Y², Wu C³, Tang C³, Kuo L¹, ¹Taipei Medical University and Wan Fang Hospital, Taipei, Taiwan, ²Taipei Medical University, Taipei, Taiwan, ³Taipei Medical University, Taipei City, Taiwan

**PMS8 S2** HOSPITAL ADMISSIONS AND INPATIENT COSTS OF NON-UNION, DELAYED UNION AND MAL-UNION FOLLOWING LONG BONE FRACTURE
Dunlop S¹, Ekegren CL², Edwards ER³, de Steiger R³, Page R³, Gabbe BJ³, ¹Zimmer Biomet, Belrose, Australia, ²Monash University, Melbourne, Australia, ³The Alfred Hospital, Prahran, Australia, ⁴Epworth Hospital, Richmond, Australia, ⁵University Hospital Geelong, Geelong, Australia

**PMS9 S3** MODELING THE COST-EFFECTIVENESS OF STATIN THERAPY IN RHEUMATOID ARTHRITIS A MARKOV-CYCLE EVALUATION FROM THE NATIONAL DATA BANK FOR RHEUMATIC DISEASES
Almasri D¹, Lai L², Michaud K³, ¹King Abdulaziz University, Jeddah, Saudi Arabia, ²Nova Southeastern University, Davie, FL, USA, ³University of Nebraska Medical Center, Omaha, NE, USA

**PMS10 S4** EVALUATE THE COST-EFFECTIVE THRESHOLD OF OSTEOPOROSIS TREATMENT ON ELDERLY WOMEN IN CHINA USING DISCRETE EVENT SIMULATION MODEL
Ni W, Jiang Y, University of Southern California, Los Angeles, CA, USA

**PMS11 S5** COST-EFFECTIVENESS OF BISPHOSPHONATES FOR PRIMARY AND SECONDARY PREVENTION OF HIP-RELATED FRACTURE WITH GLUCOCORTICOID-INDUCED OSTEOPEOROSIS IN MALAYSIA
Mohd Tahir NA¹, Thomas P², Makmor Bakry M³, Mohamed Said MS⁴, Li SC¹, ¹University of Newcastle, Callaghan, NSW, Australia, ²Taylor's University, Selangor, Malaysia, ³Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia, ⁴Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia

**PMS12 S6** ECONOMIC EVALUATION OF DIACEREIN, DICLOFENAC AND GLUCOSAMINE FOR OSTEOARTHRITIS IN CHINA
Li H¹, Ma A¹, Tian L¹, Fu Y¹, Liu G², ¹China Pharmaceutical University, Nanjing, China, ²Peking University, Beijing, China

**MUSCULAR-SKELETAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies**

**PMS13 S7** TREATMENT SATISFACTION OF OSTEOPOROSIS MEDICATION IN POSTMENOPAUSAL WOMEN OF KOREA; RESULTS FROM THE STUDY OF OSTEOPOROSIS MEDICATION ADHERENCE AND SATISFACTION IN POSTMENOPAUSAL WOMEN
Byun D¹, Moon S², Kim T³, Kim Y³, Seo B⁴, Min Y⁵, ¹Soochunhyang University Hospital, Seoul, South Korea, ²Yonsei University College of Medicine, Seoul, South Korea, ³College of Medicine, Korea University, Seoul, South Korea, ⁴Pﬁzer Pharmaceuticals Korea Ltd., Seoul, South Korea, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

**PMS14 S8** HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS AT UTTARADIT HOSPITAL,
THAILAND
Pongmesa T1, Munchey R2, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand, Nampad Hospital, Uttaradit, Thailand

PMS15 S9 PSYCHOLOGICAL DISTRESS IN CHINESE PATIENTS WITH RHEUMATOID ARTHRITIS AND PSYCHOMETRIC VALIDATION OF CHINESE HOSPITAL ANXIETY AND DEPRESSION SCALE
Hu H1, Luan L1, Yang KQ2, Li SC1, University of Newcastle, Callaghan, NSW, Australia, Taizhou No.4 Renmin Hospital, Jiangsu, China

PMS16 S10 PRODUCTIVITY LOSS OF RHEUMATOID ARTHRITIS PATIENTS BY THEIR LEVEL OF DISEASE ACTIVITY SCORE
Bae S1, Koh H2, Kim Y2, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, Pfizer Pharmaceuticals Korea Limited, Seoul, South Korea

MUSCULAR-SKELETAL DISORDERS - Health Care Use & Policy Studies

PMS18 T1 TREATMENT GAP OF POST OSTEOPOROTIC FRACTURES IN TAIWAN: A NATIONWIDE COHORT STUDY, 2008-2013
Wang C1, Fu S2, Huang C2, Hung C3, Huang S1, Lin C4, Hsiao F4, School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan, Department of orthopedics, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin County, Taiwan, Yunlin, Taiwan, National Taiwan University, Taipei, Taiwan

PMS19 T2 PERSISTENCE WITH BIOLOGIC AGENTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN JAPAN
Mahlich JC1, Sruamsiri R2, Janssen KK, Tokyo, Japan, Janssen Pharmaceutical KK, Tokyo, Japan

PMS20 T3 TREATMENT PATTERNS OF RHEUMATOID ARTHRITIS IN JAPANESE HOSPITALS AND PREDICTORS OF INITIATION BIOLOGIC AGENTS
Mahlich JC1, Sruamsiri R2, Janssen KK, Tokyo, Japan, Janssen Pharmaceutical KK, Tokyo, Japan

PMS21 T4 MAPPING THE PRESCRIPTION TREND FOR RHEUMATOID ARTHRITIS IN MUMBAI, INDIA
Kulkarni AS, Kelkar RS, Majumdar AS, Bombay College of Pharmacy, Mumbai, India